Page last updated: 2024-12-08

pralnacasan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pralnacasan: NSAID, ICE inhibitor & metastasis inhibitor; RN & structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID153270
CHEMBL ID437526
SCHEMBL ID142187
MeSH IDM0452698

Synonyms (36)

Synonym
pralnacasan
(1s,9s)-n-((2r,3s)-2-ethoxy-5-oxo-tetrahydrofuran-3-yl)-9-(isoquinoline-1-carboxamido)-6,10-dioxo-octahydro-1h-pyridazino[1,2-a][1,2]diazepine-1-carboxamide
(1s,10s)-9-[(isoquinoline-1-carbonyl)-amino]-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid ((s)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide
bdbm50189360
(4s,7s)-n-[(2r,3s)-2-ethoxy-5-oxooxolan-3-yl]-7-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1h-pyridazino[1,2-a]diazepine-4-carboxamide
pralnacasan (usan/inn)
D08978
192755-52-5
hmr 3480
6h-pyridazino(1,2-a)(1,2)diazepine-1-carboxamide, n-((2r,3s)-2-ethoxytetrahydro-5-oxo-3-furanyl)octahydro-9-((1-isoquinolinylcarbonyl)amino)-6,10-dioxo-, (1s,9s)-
vx 470
n986ni319s ,
hmr3480
pralnacasan [usan:inn]
hmr3480/vx-740
vx-740
unii-n986ni319s
(1s,9s)-n-((2r,3s)-2-ethoxy-5-oxotetrahydrofuran-3-yl)-9-((isoquinolin-1-ylcarbonyl)amino)-6,10-dioxooctahydro-6-h-pyridazino(1,2-a)(1,2)diazepine-1-carboxamide
CHEMBL437526
hmr-3480
vx740
gtpl6467
(1s,9s)-n-[(2r,3s)-2-ethoxy-5-oxooxolan-3-yl]-9-(isoquinoline-1-carbonylamino)-6,10-dioxo-2,3,4,7,8,9-hexahydro-1h-pyridazino[1,2-a]diazepine-1-carboxamide
pralnacasan [usan]
hmr-3480/vx-740
pralnacasan [inn]
DB04875
SCHEMBL142187
DTXSID60172873
AKOS030230853
HY-19676
Q27088439
CS-0016191
MS-29694
(1s,9s)-n-((2r,3s)-2-ethoxy-5-oxotetrahydrofuran-3-yl)-9-(isoquinoline-1-carboxamido)-6,10-dioxooctahydro-6h-pyridazino[1,2-a][1,2]diazepine-1-carboxamide
(3s,11s)-n-[(2r,3s)-2-ethoxy-5-oxo-oxolan-3-yl]-3-(isoquinoline-1-carbonylamino)-2,6-dioxo-1,7-diazabicyclo[5.4.0]undecane-11-carboxamide

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"To study the effect of pralnacasan, the orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE), RU 36384/VRT-18858, on joint damage in two mouse models of knee osteoarthritis (OA)."( Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis.
Gerwin, N; Rudolphi, K; van den Berg, W; van der Kraan, P; Verzijl, N, 2003
)
2.07

Dosage Studied

ExcerptRelevanceReference
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Caspase-1Homo sapiens (human)IC50 (µMol)0.10730.00201.70138.8000AID1286190; AID254996; AID269766; AID270959
Caspase-3Homo sapiens (human)IC50 (µMol)1.30000.00021.19798.8000AID270963
Caspase-8Homo sapiens (human)IC50 (µMol)0.04000.00220.68455.0000AID269767; AID270960
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (102)

Processvia Protein(s)Taxonomy
cellular response to organic substanceCaspase-1Homo sapiens (human)
pattern recognition receptor signaling pathwayCaspase-1Homo sapiens (human)
proteolysisCaspase-1Homo sapiens (human)
apoptotic processCaspase-1Homo sapiens (human)
signal transductionCaspase-1Homo sapiens (human)
osmosensory signaling pathwayCaspase-1Homo sapiens (human)
protein autoprocessingCaspase-1Homo sapiens (human)
positive regulation of interleukin-1 beta productionCaspase-1Homo sapiens (human)
positive regulation of interleukin-18 productionCaspase-1Homo sapiens (human)
defense response to bacteriumCaspase-1Homo sapiens (human)
regulation of apoptotic processCaspase-1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionCaspase-1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processCaspase-1Homo sapiens (human)
icosanoid biosynthetic processCaspase-1Homo sapiens (human)
regulation of inflammatory responseCaspase-1Homo sapiens (human)
positive regulation of inflammatory responseCaspase-1Homo sapiens (human)
protein maturationCaspase-1Homo sapiens (human)
defense response to virusCaspase-1Homo sapiens (human)
pyroptosisCaspase-1Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-1Homo sapiens (human)
cellular response to mechanical stimulusCaspase-1Homo sapiens (human)
cellular response to type II interferonCaspase-1Homo sapiens (human)
cytokine precursor processingCaspase-1Homo sapiens (human)
signaling receptor ligand precursor processingCaspase-1Homo sapiens (human)
AIM2 inflammasome complex assemblyCaspase-1Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayCaspase-1Homo sapiens (human)
neurotrophin TRK receptor signaling pathwayCaspase-3Homo sapiens (human)
luteolysisCaspase-3Homo sapiens (human)
response to hypoxiaCaspase-3Homo sapiens (human)
B cell homeostasisCaspase-3Homo sapiens (human)
negative regulation of cytokine productionCaspase-3Homo sapiens (human)
proteolysisCaspase-3Homo sapiens (human)
apoptotic processCaspase-3Homo sapiens (human)
DNA damage responseCaspase-3Homo sapiens (human)
axonal fasciculationCaspase-3Homo sapiens (human)
heart developmentCaspase-3Homo sapiens (human)
sensory perception of soundCaspase-3Homo sapiens (human)
learning or memoryCaspase-3Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to osmotic stressCaspase-3Homo sapiens (human)
response to xenobiotic stimulusCaspase-3Homo sapiens (human)
response to UVCaspase-3Homo sapiens (human)
response to woundingCaspase-3Homo sapiens (human)
response to glucoseCaspase-3Homo sapiens (human)
response to X-rayCaspase-3Homo sapiens (human)
regulation of macroautophagyCaspase-3Homo sapiens (human)
protein processingCaspase-3Homo sapiens (human)
hippocampus developmentCaspase-3Homo sapiens (human)
protein catabolic processCaspase-3Homo sapiens (human)
erythrocyte differentiationCaspase-3Homo sapiens (human)
platelet formationCaspase-3Homo sapiens (human)
negative regulation of B cell proliferationCaspase-3Homo sapiens (human)
regulation of protein stabilityCaspase-3Homo sapiens (human)
response to cobalt ionCaspase-3Homo sapiens (human)
response to estradiolCaspase-3Homo sapiens (human)
response to lipopolysaccharideCaspase-3Homo sapiens (human)
glial cell apoptotic processCaspase-3Homo sapiens (human)
response to tumor necrosis factorCaspase-3Homo sapiens (human)
response to nicotineCaspase-3Homo sapiens (human)
response to hydrogen peroxideCaspase-3Homo sapiens (human)
T cell homeostasisCaspase-3Homo sapiens (human)
response to amino acidCaspase-3Homo sapiens (human)
fibroblast apoptotic processCaspase-3Homo sapiens (human)
cell fate commitmentCaspase-3Homo sapiens (human)
negative regulation of cell cycleCaspase-3Homo sapiens (human)
negative regulation of activated T cell proliferationCaspase-3Homo sapiens (human)
striated muscle cell differentiationCaspase-3Homo sapiens (human)
response to glucocorticoidCaspase-3Homo sapiens (human)
neuron apoptotic processCaspase-3Homo sapiens (human)
protein maturationCaspase-3Homo sapiens (human)
anterior neural tube closureCaspase-3Homo sapiens (human)
pyroptosisCaspase-3Homo sapiens (human)
leukocyte apoptotic processCaspase-3Homo sapiens (human)
cellular response to staurosporineCaspase-3Homo sapiens (human)
apoptotic signaling pathwayCaspase-3Homo sapiens (human)
intrinsic apoptotic signaling pathwayCaspase-3Homo sapiens (human)
execution phase of apoptosisCaspase-3Homo sapiens (human)
positive regulation of pyroptosisCaspase-3Homo sapiens (human)
positive regulation of amyloid-beta formationCaspase-3Homo sapiens (human)
epithelial cell apoptotic processCaspase-3Homo sapiens (human)
keratinocyte differentiationCaspase-3Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-3Homo sapiens (human)
neuron differentiationCaspase-3Homo sapiens (human)
angiogenesisCaspase-8Homo sapiens (human)
regulation of cytokine productionCaspase-8Homo sapiens (human)
proteolysisCaspase-8Homo sapiens (human)
apoptotic processCaspase-8Homo sapiens (human)
heart developmentCaspase-8Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwayCaspase-8Homo sapiens (human)
natural killer cell activationCaspase-8Homo sapiens (human)
macrophage differentiationCaspase-8Homo sapiens (human)
positive regulation of cell migrationCaspase-8Homo sapiens (human)
response to cobalt ionCaspase-8Homo sapiens (human)
response to estradiolCaspase-8Homo sapiens (human)
response to lipopolysaccharideCaspase-8Homo sapiens (human)
positive regulation of interleukin-1 beta productionCaspase-8Homo sapiens (human)
response to tumor necrosis factorCaspase-8Homo sapiens (human)
TRAIL-activated apoptotic signaling pathwayCaspase-8Homo sapiens (human)
T cell activationCaspase-8Homo sapiens (human)
B cell activationCaspase-8Homo sapiens (human)
positive regulation of apoptotic processCaspase-8Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionCaspase-8Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionCaspase-8Homo sapiens (human)
regulation of innate immune responseCaspase-8Homo sapiens (human)
response to ethanolCaspase-8Homo sapiens (human)
positive regulation of macrophage differentiationCaspase-8Homo sapiens (human)
positive regulation of proteolysisCaspase-8Homo sapiens (human)
proteolysis involved in protein catabolic processCaspase-8Homo sapiens (human)
protein maturationCaspase-8Homo sapiens (human)
negative regulation of necroptotic processCaspase-8Homo sapiens (human)
syncytiotrophoblast cell differentiation involved in labyrinthine layer developmentCaspase-8Homo sapiens (human)
pyroptosisCaspase-8Homo sapiens (human)
cellular response to mechanical stimulusCaspase-8Homo sapiens (human)
cellular response to organic cyclic compoundCaspase-8Homo sapiens (human)
apoptotic signaling pathwayCaspase-8Homo sapiens (human)
extrinsic apoptotic signaling pathwayCaspase-8Homo sapiens (human)
execution phase of apoptosisCaspase-8Homo sapiens (human)
activation of cysteine-type endopeptidase activityCaspase-8Homo sapiens (human)
self proteolysisCaspase-8Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processCaspase-8Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsCaspase-8Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (25)

Processvia Protein(s)Taxonomy
endopeptidase activityCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-1Homo sapiens (human)
protein bindingCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processCaspase-1Homo sapiens (human)
kinase bindingCaspase-1Homo sapiens (human)
cytokine bindingCaspase-1Homo sapiens (human)
identical protein bindingCaspase-1Homo sapiens (human)
CARD domain bindingCaspase-1Homo sapiens (human)
caspase bindingCaspase-1Homo sapiens (human)
protease bindingCaspase-3Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-3Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase inhibitor activityCaspase-3Homo sapiens (human)
death receptor bindingCaspase-3Homo sapiens (human)
protein bindingCaspase-3Homo sapiens (human)
peptidase activityCaspase-3Homo sapiens (human)
phospholipase A2 activator activityCaspase-3Homo sapiens (human)
protein-containing complex bindingCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic signaling pathwayCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-3Homo sapiens (human)
enzyme activator activityCaspase-3Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-8Homo sapiens (human)
death receptor bindingCaspase-8Homo sapiens (human)
tumor necrosis factor receptor bindingCaspase-8Homo sapiens (human)
protein bindingCaspase-8Homo sapiens (human)
peptidase activityCaspase-8Homo sapiens (human)
cysteine-type peptidase activityCaspase-8Homo sapiens (human)
ubiquitin protein ligase bindingCaspase-8Homo sapiens (human)
death effector domain bindingCaspase-8Homo sapiens (human)
identical protein bindingCaspase-8Homo sapiens (human)
protein-containing complex bindingCaspase-8Homo sapiens (human)
scaffold protein bindingCaspase-8Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-8Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic signaling pathwayCaspase-8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
nucleolusCaspase-1Homo sapiens (human)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
microtubuleCaspase-1Homo sapiens (human)
plasma membraneCaspase-1Homo sapiens (human)
canonical inflammasome complexCaspase-1Homo sapiens (human)
NLRP1 inflammasome complexCaspase-1Homo sapiens (human)
NLRP3 inflammasome complexCaspase-1Homo sapiens (human)
AIM2 inflammasome complexCaspase-1Homo sapiens (human)
protein-containing complexCaspase-1Homo sapiens (human)
IPAF inflammasome complexCaspase-1Homo sapiens (human)
protease inhibitor complexCaspase-1Homo sapiens (human)
nucleusCaspase-3Homo sapiens (human)
cytoplasmCaspase-3Homo sapiens (human)
nucleusCaspase-3Homo sapiens (human)
nucleoplasmCaspase-3Homo sapiens (human)
cytosolCaspase-3Homo sapiens (human)
neuronal cell bodyCaspase-3Homo sapiens (human)
death-inducing signaling complexCaspase-3Homo sapiens (human)
cytoplasmCaspase-8Homo sapiens (human)
nucleoplasmCaspase-8Homo sapiens (human)
mitochondrionCaspase-8Homo sapiens (human)
mitochondrial outer membraneCaspase-8Homo sapiens (human)
cytosolCaspase-8Homo sapiens (human)
cytoskeletonCaspase-8Homo sapiens (human)
lamellipodiumCaspase-8Homo sapiens (human)
cell bodyCaspase-8Homo sapiens (human)
death-inducing signaling complexCaspase-8Homo sapiens (human)
CD95 death-inducing signaling complexCaspase-8Homo sapiens (human)
protein-containing complexCaspase-8Homo sapiens (human)
ripoptosomeCaspase-8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID269766Inhibition of ICE2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Synthesis and evaluation of novel 1-(2-acylhydrazinocarbonyl)-cycloalkyl carboxamides as interleukin-1beta converting enzyme (ICE) inhibitors.
AID270959Inhibition of ICE2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Synthesis and evaluation of thiazepines as interleukin-1beta converting enzyme (ICE) inhibitors.
AID270961Inhibition of LPS-induced ILbeta1 release in human THP1 cells2006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Synthesis and evaluation of thiazepines as interleukin-1beta converting enzyme (ICE) inhibitors.
AID255953Inhibition of 1 ug/mL LPS-induced IL1-beta production in human monocytic cells after 4 hrs2005Bioorganic & medicinal chemistry letters, Oct-01, Volume: 15, Issue:19
Discovery of novel conformationally restricted diazocan peptidomimetics as inhibitors of interleukin-1beta synthesis.
AID625293Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in LTKB-BD2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID270963Inhibition of Caspase 32006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Synthesis and evaluation of thiazepines as interleukin-1beta converting enzyme (ICE) inhibitors.
AID269767Inhibition of caspase82006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Synthesis and evaluation of novel 1-(2-acylhydrazinocarbonyl)-cycloalkyl carboxamides as interleukin-1beta converting enzyme (ICE) inhibitors.
AID269769Inhibition of IL1-beta secretion in human THP1 cells2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Synthesis and evaluation of novel 1-(2-acylhydrazinocarbonyl)-cycloalkyl carboxamides as interleukin-1beta converting enzyme (ICE) inhibitors.
AID254996Inhibition of caspase-1 using fluorogenic substrate and BMG Fluostar plate reader for 30 min at 37 degree C2005Bioorganic & medicinal chemistry letters, Oct-01, Volume: 15, Issue:19
Discovery of novel conformationally restricted diazocan peptidomimetics as inhibitors of interleukin-1beta synthesis.
AID1286190Inhibition of caspase-1 in LPS stimulated human PMBC cells after 2 hrs by ELISA analysis2016Journal of medicinal chemistry, Mar-10, Volume: 59, Issue:5
Inhibiting the Inflammasome: A Chemical Perspective.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID270960Inhibition of Caspase 82006Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
Synthesis and evaluation of thiazepines as interleukin-1beta converting enzyme (ICE) inhibitors.
AID1346687Human Caspase 1 (C14: Caspase)2005Current topics in medicinal chemistry, , Volume: 5, Issue:16
Caspase inhibitors: a pharmaceutical industry perspective.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's12 (63.16)29.6817
2010's6 (31.58)24.3611
2020's1 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.98 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (26.32%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (73.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]